Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Pulmonx has a consensus analyst rating of "Hold" from eight firms (1 sell, 3 hold, 4 buy) with an average 1‑year price target of $5.38.
• Shares trade around $1.35 (52‑week range $1.13–$3.89) and the company remains unprofitable, reporting Q1 EPS of $(0.33) (met estimates), a net margin of −60.09% and ROE of −87.11%, with analysts forecasting about −$1.12 EPS for the year; market cap is roughly $57M.
• Insiders have been selling (CEO sold 67,813 shares at $1.43; 98,265 shares sold this quarter), yet institutional ownership is high (~91%) with notable new or increased stakes from Norges Bank, Bank of America and Jane Street.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has received an average rating of "Hold" from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $5.3786.

Several brokerages recently issued reports on LUNG. Wall Street Zen downgraded shares of Pulmonx from a "hold" rating to a "sell" rating in a research note on Saturday. Weiss Ratings reiterated a "sell (e+)" rating on shares of Pulmonx in a research note on Thursday, January 22nd. Canaccord Genuity Group lowered their price target on shares of Pulmonx from $6.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Finally, D. Boral Capital reissued a "buy" rating and issued a $14.00 price target on shares of Pulmonx in a report on Thursday.

Pulmonx Trading Up 5.5%

Shares of NASDAQ:LUNG opened at $1.35 on Friday. Pulmonx has a 52-week low of $1.13 and a 52-week high of $3.89. The company has a market capitalization of $57.02 million, a P/E ratio of -1.04 and a beta of 0.18. The company has a 50-day simple moving average of $1.44 and a 200 day simple moving average of $1.71. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.28 and a current ratio of 5.07.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 87.11%. The business had revenue of $20.59 million during the quarter, compared to the consensus estimate of $20.43 million. Sell-side analysts forecast that Pulmonx will post -1.12 earnings per share for the current year.

Insiders Place Their Bets

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the transaction, the chief executive officer directly owned 1,409,511 shares of the company's stock, valued at $2,015,600.73. This represents a 4.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 98,265 shares of company stock valued at $140,519. 6.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LUNG. XTX Topco Ltd bought a new position in Pulmonx in the 2nd quarter valued at about $149,000. Norges Bank bought a new position in Pulmonx in the 2nd quarter valued at about $392,000. Jane Street Group LLC raised its holdings in Pulmonx by 3,328.7% in the 2nd quarter. Jane Street Group LLC now owns 88,631 shares of the company's stock valued at $230,000 after acquiring an additional 86,046 shares during the period. Bank of America Corp DE raised its holdings in Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company's stock valued at $1,246,000 after acquiring an additional 407,971 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Pulmonx by 95.8% in the 3rd quarter. SG Americas Securities LLC now owns 24,863 shares of the company's stock valued at $40,000 after acquiring an additional 12,166 shares during the period. 91.04% of the stock is owned by institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.